Thomas A. Vecchiolla - 21 Dec 2023 Form 4 Insider Report for Calidi Biotherapeutics, Inc. (CLDI)

Reporting relationship: Director
Issuer ticker: CLDI
Reported as of: 21 Dec 2023
Net transaction value: +$13,876
SEC form: 4
Accepted by SEC: 26 Dec 2023, 19:52:21 UTC
Prior SEC filing: 14 Sep 2023
Source filing: View source filing
Reporting owner signature: /s/ Thomas Vecchiolla

Key filing fact

Thomas A. Vecchiolla filed Form 4 for Calidi Biotherapeutics, Inc. (CLDI) on 26 Dec 2023.

Key facts

This page summarizes Thomas A. Vecchiolla's Form 4 filing for Calidi Biotherapeutics, Inc. (CLDI).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 26 Dec 2023, 19:52.

Change

Previous filing in this sequence was filed on 14 Sep 2023.
Current net transaction value: +$13,876.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CLDI transaction

Common Stock

Award

Transaction value: $13,876
Shares: +7,709
Change %: +2.2%
Price: $1.80
Shares after: 365,105
Date: 21 Dec 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents a grant of restricted stock units ("RSUs") subject to the conditions of the Restricted Stock Unit Award Agreement pursuant to the Issuer's 2023 Plan. Each RSU represents a right to receive one share of the Company's common stock upon vesting. The number of RSUs to be issued will equal to the amount due to the director for Board fees divided by the closing price for a share of the Issuer's common stock on December 21, 2023, of $1.80. The RSUs were granted in a transaction exempt under Rule 16b-3 to the Reporting Person. The shares of common stock underlying the RSUs immediately vested on the grant date.